BTK
Os inibidores da tirosina quinase de Bruton (BTK) são compostos que especificamente têm como alvo e inibem a BTK, uma enzima crucial envolvida na sinalização do receptor de células B e na regulação da angiogênese. A BTK desempenha um papel significativo na proliferação e sobrevivência de células cancerígenas, particularmente em malignidades hematológicas. Ao inibir a BTK, esses compostos podem interromper a angiogênese e o crescimento tumoral, tornando-os valiosos na terapia do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de BTK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 168 produtos para "BTK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
G-744
CAS:G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).Fórmula:C29H29N5O3SPureza:98%Cor e Forma:SolidPeso molecular:527.64JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Fórmula:C21H25ClN8OCor e Forma:SolidPeso molecular:440.93BTK-IN-38
CAS:BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.Fórmula:C27H26F2N4O2Cor e Forma:SolidPeso molecular:476.52WS-11
CAS:WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Fórmula:C26H22FN9O2Cor e Forma:SolidPeso molecular:511.51GNE-431
CAS:GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Fórmula:C30H32N10O2Cor e Forma:SolidPeso molecular:564.64TQ-3959
CAS:TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Fórmula:C40H47N11O5Cor e Forma:SolidPeso molecular:761.87HDHD4-IN-1
CAS:HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Fórmula:C12H22NO11PCor e Forma:SolidPeso molecular:387.28BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Fórmula:C26H36N6O3Cor e Forma:SolidPeso molecular:480.6CFON-026
CAS:CFON-026 is a selective, orally active, non-covalent BTK inhibitor with an IC50 of 0.27 nM. It demonstrates significant antitumor activity against wild-type BTK (TMD8 and REC-1) as well as all clinically relevant BTK resistance mutations (BTKC481S, T474I, L528W, and V416L). CFON-026 induces complete tumor regression in the TMD8 xenograft mouse model. This compound is applicable for research into hematologic cancers, such as chronic lymphocytic leukemia and Waldenström's macroglobulinemia.Fórmula:C33H34N8O2Peso molecular:574.68BTK-IN-16
CAS:BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.Fórmula:C15H14N4O2Pureza:99.04%Cor e Forma:SoildPeso molecular:282.3BTK-IN-34
CAS:BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Fórmula:C22H29N3O4SCor e Forma:SolidPeso molecular:431.55BIIB129
CAS:BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.Fórmula:C19H22N6O2Pureza:98.56%Cor e Forma:Yellow SolidPeso molecular:366.42BTK degrader-1 intermediate
CAS:BTKdegrader-1 intermediate (compound 5) is a precursor in the synthesis of BTKdegrader-1, which serves as a toxin for Antibody-drug Conjugates (ADC) used in developing related molecules.Fórmula:C40H44F2N6O2Cor e Forma:SolidPeso molecular:678.81BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Fórmula:C23H22FN5O3Cor e Forma:SolidPeso molecular:435.45(Rac)-Ibrutinib alkyne
CAS:(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Fórmula:C25H22N6O2Cor e Forma:SolidPeso molecular:438.48UBX-382
CAS:UBX-382 is an orally administered proteolysis-targeting chimera (PROTAC) designed to target BTK and disrupt B-cell receptor signaling. It demonstrates enhanced degradation of both wild-type and mutant BTK proteins, exhibiting anti-cancer effects in murine xenograft models using TMD-8 cells [1].Fórmula:C42H44N10O4Cor e Forma:SolidPeso molecular:752.86BTK-IN-32
CAS:BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Fórmula:C35H35ClN4O3SCor e Forma:SolidPeso molecular:627.2Vecabrutinib
CAS:Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.Fórmula:C22H24ClF4N7O2Pureza:99.74%Cor e Forma:SolidPeso molecular:529.92Ref: TM-T17220
1mg82,00€5mg177,00€1mL*10mM (DMSO)207,00€10mg289,00€25mg470,00€50mg623,00€100mg874,00€
